Literature DB >> 17516089

Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells.

E Kassi1, Z Papoutsi, H Pratsinis, N Aligiannis, M Manoussakis, P Moutsatsou.   

Abstract

PURPOSE: Glucocorticoids are widely used as adjuvant therapy in hormonal refractory prostate cancer; their therapeutic role, however, remains unclear. Ursolic acid, a natural triterpene, structurally similar to dexamethasone, exhibits antitumor effects in various cell types. Our main objective was to investigate the effects of ursolic acid on cell viability, apoptosis and bcl-2 protein, in human hormone refractory and androgen-sensitive prostate cancer cells.
METHODS: The ursolic acid-induced changes in cell viability, apoptosis and bcl-2 protein were examined in human hormone refractory prostate cancer PC-3 cells and androgen-sensitive LNCaP cells, by MTT assay, flow cytometry and western blot analysis, respectively.
RESULTS: Ursolic acid inhibited significantly the cell viability and induced apoptosis in PC-3 cells at 55 microM and in LNCaP cells at 45 microM associated with a downregulation of bcl-2 protein.
CONCLUSIONS: The antiproliferative and apoptotic effects of ursolic acid in PC-3 and LNCaP cells implicate its potential therapeutic use for the treatment of hormone refractory and androgen-sensitive prostate cancer. The downregulation of bcl-2 may be one of the molecular mechanisms via which it induces apoptosis in PC-3 and LNCaP cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516089     DOI: 10.1007/s00432-007-0193-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  34 in total

Review 1.  Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.

Authors:  Marwan Fakih; Candace S Johnson; Donald L Trump
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

2.  Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells.

Authors:  H J Cha; M T Park; H Y Chung; N D Kim; H Sato; M Seiki; K W Kim
Journal:  Oncogene       Date:  1998-02-12       Impact factor: 9.867

3.  Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.

Authors:  Daniel R Budman; Anthony Calabro; Willi Kreis
Journal:  Anticancer Drugs       Date:  2002-11       Impact factor: 2.248

4.  Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.

Authors:  Yayun Liang; Manal A Eid; Fathy El Etreby; Ronald W Lewis; M Vijay Kumar
Journal:  Int J Oncol       Date:  2002-12       Impact factor: 5.650

5.  Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells.

Authors:  C B Cleutjens; K Steketee; C C van Eekelen; J A van der Korput; A O Brinkmann; J Trapman
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

Review 6.  New approaches in hormone refractory prostate cancer.

Authors:  Guru Sonpavde; Thomas E Hutson
Journal:  Am J Clin Oncol       Date:  2006-04       Impact factor: 2.339

7.  Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids.

Authors:  A L Schuurmans; J Bolt; M M Voorhorst; R A Blankenstein; E Mulder
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

8.  Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells.

Authors:  C Reyes-Moreno; G Frenette; J Boulanger; E Lavergne; M V Govindan; M Koutsilieris
Journal:  Prostate       Date:  1995-05       Impact factor: 4.104

9.  Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.

Authors:  Michael Koutsilieris; Constantine S Mitsiades; John Bogdanos; Theodoros Dimopoulos; Dimitrios Karamanolakis; Constantine Milathianakis; Athanassios Tsintavis
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

10.  Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Authors:  W K Kelly; H I Scher; M Mazumdar; D Pfister; T Curley; C Leibertz; L Cohen; V Vlamis; A Dnistrian; M Schwartz
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544

View more
  13 in total

Review 1.  Recent developments in prostate cancer biomarker research: therapeutic implications.

Authors:  Sujitra Detchokul; Albert G Frauman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.

Authors:  Muthu K Shanmugam; Peramaiyan Rajendran; Feng Li; Tarang Nema; Shireen Vali; Taher Abbasi; Shweta Kapoor; Ashish Sharma; Alan Prem Kumar; Paul C Ho; Kam M Hui; Gautam Sethi
Journal:  J Mol Med (Berl)       Date:  2011-04-05       Impact factor: 4.599

3.  In Vitro-In Vivo Dose Response of Ursolic Acid, Sulforaphane, PEITC, and Curcumin in Cancer Prevention.

Authors:  Christina N Ramirez; Wenji Li; Chengyue Zhang; Renyi Wu; Shan Su; Chao Wang; Linbo Gao; Ran Yin; Ah-Ng Kong
Journal:  AAPS J       Date:  2017-12-20       Impact factor: 4.009

4.  Correction to: In Vitro-In Vivo Dose Response of Ursolic Acid, Sulforaphane, PEITC, and Curcumin in Cancer Prevention.

Authors:  Christina N Ramirez; Wenji Li; Chengyue Zhang; Renyi Wu; Shan Su; Chao Wang; Linbo Gao; Ran Yin; Ah-Ng Tony Kong
Journal:  AAPS J       Date:  2018-02-06       Impact factor: 4.009

5.  Chloroform extract of Hedyotis diffusa Willd inhibits viability of human colorectal cancer cells via suppression of AKT and ERK signaling pathways.

Authors:  Zhaokun Yan; Jianyu Feng; Jun Peng; Zijun Lai; Ling Zhang; Yiyi Jin; Hong Yang; Wujin Chen; Jiumao Lin
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

6.  Bioassay-Guided Identification of the Antiproliferative Compounds of Cissus trifoliata and the Transcriptomic Effect of Resveratrol in Prostate Cancer Pc3 Cells.

Authors:  Luis Fernando Méndez-López; Pierluigi Caboni; Eder Arredondo-Espinoza; Juan J J Carrizales-Castillo; Isaías Balderas-Rentería; María Del Rayo Camacho-Corona
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

7.  Anticancer activity of 2α, 3α, 19β, 23β-Tetrahydroxyurs-12-en-28-oic acid (THA), a novel triterpenoid isolated from Sinojackia sarcocarpa.

Authors:  Ouchen Wang; Sujun Liu; Jiawei Zou; Liting Lu; Lin Chen; Sunquan Qiu; He Li; Xincheng Lu
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

8.  Effects of combined phytochemicals on skin tumorigenesis in SENCAR mice.

Authors:  Magdalena C Kowalczyk; Jacob J Junco; Piotr Kowalczyk; Olga Tolstykh; Margaret Hanausek; Thomas J Slaga; Zbigniew Walaszek
Journal:  Int J Oncol       Date:  2013-07-05       Impact factor: 5.650

9.  Predictive simulation approach for designing cancer therapeutic regimens with novel biological mechanisms.

Authors:  Nicole A Doudican; Amitabha Mazumder; Shweta Kapoor; Zeba Sultana; Ansu Kumar; Anay Talawdekar; Kabya Basu; Ashish Agrawal; Aditi Aggarwal; Krithika Shetty; Neeraj K Singh; Chandan Kumar; Anuj Tyagi; Neeraj Kumar Singh; Janitha C Darlybai; Taher Abbasi; Shireen Vali
Journal:  J Cancer       Date:  2014-04-25       Impact factor: 4.207

10.  Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF-κB signaling pathways in vitro.

Authors:  Juan Luo; Yan-Ling Hu; Hong Wang
Journal:  Exp Ther Med       Date:  2017-08-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.